Lipid Management for High Risk Patients - How Low Should You Target LDL-C?

Details & Video

Program Time: 30 minutes - includes presentation and interactivity
Accreditation-CME Credits: Accreditation for this activity has expired; however, Mainpro+ participants may earn certified credits by completing a Linking Learning Exercise.
Target Audience: General Practitioners
Program Preview
Click image above to play the program preview.

Overview & Objectives

How Low Should You Target LDL-C?

Target Audience: General Practitioners.

By participating in this educational program, health care providers will be able to:
  1. IDENTIFY The additional benefits of lowering LDL-C beyond the current target levels
  2. DISCUSS If LDL-C can be too low



Planning Committee & Faculty

Planning Committee & Faculty

Milan Gupta
Milan Gupta
MD, FRCPC, FCCS

Associate Clinical Professor of Medicine,
McMaster University

Medical Director
Canadian Collaborative Research Network

View disclosures

Brampton, ON
Jeffrey Habert
Jeffrey Habert
M.D., CMFC, FCMF

Assistant Professor,
University of Toronto,
Dept. of Family and Community Medicine

View disclosures

Toronto, Ontario
Daniel Ngui
Daniel Ngui
B. Sc., PT, M.D., FCMF

Clinical Associate Professor
University of British Columbia

Medical Director
Fraser Street Medical

View disclosures

Vancouver, BC
Marla Shapiro
Marla Shapiro
C.M., M.D.C.M., CMFC, M. Sc. S., FRCPC, FCMF, NCMP

Professor, University of Toronto
Department of Family and Community Medicine

University Health Network
North York General, Mount Sinai

View disclosures

Toronto, Ontario
Robert P. Giugliano
Faculty
Robert P. Giugliano
MD, SM

Senior Investigator , TIMI Study Group
CV Medicine, Brigham and Women’s Hospital
Assoc Prof of Medicine, Harvard Medical School
View disclosures

Boston, MA

Agenda

Agenda

Program ChapterDuration
(Min:Sec)
Introduction2:14
What is a "typical" cholesterol value?0:55
What we have learned about LDL-C lowering.1:04
What we have learned from PROVE-IT.1:03
What we have learned from IMPROVE-IT.2:24
What we have learned from FOURIER.7:25
What we have learned from ODYSSEY Outcomes.3:44
Cost effectiveness of PCSK9 Inhibitors1:45
Lowering LDL-C: What should we aim for?1:56


Sponsorship

CCRN sm

This program has been developed by the Canadian Collaborative Research Network, a not-for-profit physician organization, and is supported through an educational grant received from:

Amgen Canada

Links & Resources

Links & Resources:

  • O’Keefe JH et al. J Am Coll Cardiol. 2004;43:2142-2146.
  • Ballantyne CM. Am J Cardiol. 1998
  • O’Keefe JH et al, JACC 2004
  • Wiviott SD et al. J Am Coll Cardiol. 2005;46:1411-1416.
  • Cannon CP, Blazing MA, Giugliano RP, et al. NEJM. 2015;372(25):2387-2397
  • Cannon NEJM 2015;372:2387-97
  • Giugliano RP et al. JAMA Cardiol 2017; 2:547-55
  • Sabatine MS et al. Am Heart J 2016;173:94-101
  • Sabatine MS et al. New Engl J Med 2017;376:1713-22
  • Giugliano RP et al. and Sabatine MS. JAMA Cardiol 2017;2:1385-91
  • Giugliano RP et al, Lancet 2017 (on line Aug 28, 2017)
  • Giugliano RP, et al. The Lancet. 2017;390(10106):1962-1971.
  • Schwartz GG, et al. AM Heart J 2014;168:682-689.e1
  • Steg G et al. American College of Cardiology Scientific Sessions, 2018 – Orlando, FL
  • Fonarow JAMA Cardiol 2017;2:1069-78
  • Adapted from Nobel Prize Lecture, Stockholm, Sweden, 1985.
  • Science 1986;232:34
  • Sabatine and Giugliano, JAMA Cardiol 2017;2:935-6